FactaeThe Factual News

Nicox's NCX 470 treatment accepted for review in China

The NDA for NCX 470, an ophthalmological treatment, is accepted for review in China.

Published 1h1 sourceNotable
Lire en français
≈ 16s

The fact

This milestone represents a major step for Nicox in the Chinese market.

Approval could unlock new commercial opportunities.

Click the link to read an article on the topic:
Explore this topic
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.
Chine · © OpenStreetMap, OpenMapTiles, OpenFreeMapWorld map →
Follow topic →
Auto-synthesis from 1 media source · identified on September 11, 2026
← Back to home
Discover

Read more

All marches →
marches

Nicox and partner submit registration dossier for ophthalmic treatment in China

4sem · 1 sourcemarches

Nicox submits marketing authorization application for NCX 470

10sem · 1 sourcemarches

Nicox secures PDUFA date for glaucoma treatment in April 2027

2sem · 1 sourcemarches

Nicox extends its cash runway following a financial operation

1sem · 1 sourcemarches

Nicox secures backing from shareholder and strategic financial partner

11sem · 1 sourcemarches

Novo Nordisk secures Chinese approval for oral Wegovy treatment

2sem · 1 source